In rats, roxibolone counteracts the [[catabolic]] effects (control of [[nitrogen balance]]) and increased [[alkaline phosphatase]] levels induced by the potent [[glucocorticoid]] [[dexamethasone phosphate]].<ref name="pmid6523544" /> It does not bind to the [[glucocorticoid receptor]] however, and its antiglucocorticoid activity may instead be mediated by [[enzyme]] [[steroidogenesis inhibitor|inhibition]].<ref name="pmid6970661">{{cite journal |vauthors=Dahlberg E, Snochowski M, Gustafsson JA |title=Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol |journal=Endocrinology |volume=108 |issue=4 |pages=1431–40 |year=1981 |pmid=6970661 |doi=10.1210/endo-108-4-1431 |url=}}</ref> In accordance, [[11α-Hydroxyprogesterone|11α-]] and [[11β-hydroxyprogesterone]] are known to be potent [[enzyme inhibitor|inhibitor]]s of [[11β-hydroxysteroid dehydrogenase]] (11β-HSD), which is responsible for the [[biosynthesis]] of the potent [[endogenous]] glucocorticoids [[cortisol]] and [[corticosterone]] (from the [[precursor (biochemistry)|precursor]]s [[deoxycortisol]] and [[deoxycorticosterone]], respectively).<ref name="pmid7895695">{{cite journal | vauthors = Souness GW, Latif SA, Laurenzo JL, Morris DJ | title = 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat | journal = Endocrinology | volume = 136 | issue = 4 | pages = 1809–12 | year = 1995 | pmid = 7895695 | doi = 10.1210/endo.136.4.7895695 | url = }}</ref><ref name="pmid8698448">{{cite journal | vauthors = Souness GW, Morris DJ | title = 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat | journal = Hypertension | volume = 27 | issue = 3 Pt 1 | pages = 421–5 | year = 1996 | pmid = 8698448 | doi = 10.1161/01.hyp.27.3.421| url = }}</ref> As roxibolone is 11β-hydroxylated similarly, it may act in a likewise fashion. However, formebolone was found to be a very weak inhibitor of [[Corticosteroid 11-beta-dehydrogenase isozyme 2|11β-HSD type 2]], although this specific [[isoenzyme]] is responsible for the inactivation of glucocorticoids rather than their production.<ref name="pmid22273746">{{cite journal |vauthors=Fürstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A |title=The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation |journal=Toxicol. Sci. |volume=126 |issue=2 |pages=353–61 |year=2012 |pmid=22273746 |doi=10.1093/toxsci/kfs022 |url=}}</ref>
